SHOT VS KZR Stock Comparison

Performance

SHOT
100/100

SHOT returned 91.94% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

KZR
10/100

KZR returned -90.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

SHOT
10/100

Out of the last 18 quarters, SHOT has had 0 profitable quarters and has increased their profits year over year on 0 of them.

KZR
10/100

Out of the last 20 quarters, KZR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SHOT
67/100

SHOT has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

KZR
41/100

KZR has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

Analyst Price Targets

SHOT

"Analyst Price Targets" not found for SHOT

KZR
94/100

4 analysts offer 12-month price targets for KZR. Together, they have an average target of 17.5, the most optimistic target put KZR at 21 within 12-months and the most pessimistic has KZR at 14.

Sentiment

SHOT

"Sentiment" not found for SHOT

KZR
71/100

KZR had a bullish sentiment score of 71.02% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.88 comments, and 0.62 likes per day.

Technicals

SHOT

"Technicals" not found for SHOT

KZR
29/100

KZR receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

Earnings

SHOT

"Earnings" not found for SHOT

KZR
10/100

KZR has missed earnings 6 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Safety Shot, Inc. Common Stock Summary

Nasdaq / SHOT

Healthcare

Drug Manufacturers - Specialty & Generic

Jupiter Wellness, Inc., a wellness company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women's sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.

Kezar Life Sciences, Inc. Common Stock Summary

Nasdaq / KZR

Healthcare

Biotechnology

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Power up your portfolio